Close Menu

NEW YORK – Spectrum Pharmaceuticals said on Monday after the market closed that poziotinib met its primary endpoint of objective response rate and shrunk tumors in lung cancer patients in the Phase II ZENITH20 trial.

Cohort 2 of the ZENITH20 study included 90 previously treated non-small cell lung cancer patients with HER2 exon 20 insertions. They received an oral, once daily dose of 16 mg of poziotinib, and nearly 28 percent saw their tumors shrink.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.